Summary
Bristol-Myers Squibb Company (BMY) has filed an 8-K report on February 6, 2025, to announce its financial results for the fourth quarter and full year of 2024. The filing includes a press release detailing these results, which investors should review for a comprehensive understanding of the company's performance. This report also references a supplemental presentation available on the company's website, offering further insights into financial and operational initiatives. Investors should note that both the press release and presentation contain non-GAAP financial measures, with reconciliations provided in the press release. This 8-K serves as a notification and furnishing of material information, rather than a definitive filing with liabilities under Section 18 of the Exchange Act, for the information furnished under Item 7.01. The company's decision to make the presentation available on its website is subject to change. Investors seeking detailed financial performance, strategic updates, and forward-looking statements will find the most crucial information within the furnished press release and presentation materials.
Key Highlights
- 1BMY filed an 8-K on February 6, 2025, announcing Q4 and full-year 2024 financial results.
- 2The report includes a press release (Exhibit 99.1) containing detailed financial and operational information for the reported periods.
- 3A supplemental presentation (Exhibit 99.2) on financial and operating initiatives is also furnished and available on the company's website.
- 4Both the press release and presentation reference non-GAAP financial information, with reconciliations provided in the press release.
- 5The information furnished under Item 7.01 is not considered 'filed' for Section 18 of the Exchange Act purposes.
- 6Investors should refer to Exhibit 99.1 and Exhibit 99.2 for the most pertinent financial and operational disclosures.